Ambrosia Biosciences Raises Million Series B for Oral GLP-1 Obesity Pill
Former Array BioPharma Scientists Take Aim at Injectable Wegovy with Oral Alternative
Ambrosia Biosciences has landed a million oversubscribed Series B round to advance its small molecule GLP-1 pill designed to compete with recently approved oral Wegovy and Eli Lilly newly approved Foundayo.
The Opportunity
The obesity drug market is undergoing a transformation from injectable to oral formulations:
- Novo Nordisk oral Wegovy approved December 2025
- Eli Lilly orforglipron (Foundayo) approved April 2026
- Ambrosia aims to offer a more convenient, combinable small molecule alternative
Ambrosia Portfolio
The Colorado-based biotech is developing drugs targeting multiple metabolic pathways:
- GLP-1 receptor modulators
- GIP receptor modulators
- Amylin receptor modulators
CEO Nick Traggis emphasized the opportunity for differentiated small molecules designed with combinability in mind as the field moves beyond first-generation molecules.
Funding Details
- Series B: million (oversubscribed)
- Co-led by: Blue Owl Healthcare Opportunities, Redmile, Deep Track Capital
- Previous round: million Series A in 2024
- Use of proceeds: Advance portfolio into early human testing
Company Origins
Ambrosia was founded by former Array BioPharma scientists who were laid off after Pfizer acquired the cancer drugmaker. This is a common pattern in biotech, where pharmaceutical mergers create pools of experienced talent that spin out into new ventures.
Market Context
The oral obesity drug market is rapidly becoming the next major battleground in pharmaceuticals. With multiple oral GLP-1 options either approved or in development, the competition will likely focus on efficacy, convenience, and ability to combine with other therapies for enhanced weight loss.
Source: BioPharma Dive https://www.biopharmadive.com/news/ambrosia-obesity-GLP-1-pill-series-b/816317/